CANNABIS BREATHALIZER AND DRIVING
Medical marijuana regulators approved 12 new dispensaries Thursday to open in the state, more than doubling the number of businesses allowed to sell the drug. But they cautioned the supply remains low, and it may be difficult to buy marijuana until at least March. Eventually there will be two dispensaries per senatorial district, so about 100 in total in the entire state of Maryland.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC - the psychoactive component of marijuana that causes intoxication - using breath samples. In Particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
Those who consume cannabis long-term suffer no greater likelihood of cardiovascular disease by middle age than do those with no history of use, according to longitudinal data published online ahead of print in the American Journal of Public Health.
An international team of researchers from the United States and Switzerland assessed cumulative cannabis use and cardiovascular risk in a cohort of over 5,000 subjects over a period of more than two decades. Authors reported, "Compared with no marijuana use, cumulative lifetime and recent marijuana use showed no association with incident CVD (cardiovascular disease), stroke or transient ischemic attacks, coronary heart disease, or CVD mortality."
They concluded, "In this community-based cohort of young adults followed for more than 25 years, we found no evidence to suggest that cumulative lifetime or recent marijuana use, at levels typical of most recreational, occasional users of marijuana in the United States, affects risk of future CVD events through middle age."
MARYLAND CANNABIS AND CBD
Maryland dispensaries are currently being supplied with medical cannabis that lacks one of the main medicinal components - CBD - or cannabidiol. Many medical conditions are best treated with strains (chemovars) of cannabis that has a presence of CBD, usually lower in percentage than the THC content, but nonetheless present in some amount to insure the proper medicinal effect of the plant. Without the CBD, many of the beneficial effects for treatment of disease are missed.... This is perhaps a glaring omission in the rollout of the program!! Future strains will certainly be available with CBD, but for now they are difficult or impossible to find at the dispensaries. For this reason, there are patients using cannabis currently from Md. dispensaries that are not achieving the result that they desire. Let's hope this situation is rectified soon.... make sure to always check the THC:CBD ratio, and insure that this ingredient is present in your cannabis. CBD is not psychoactive, but is physiologically active and effective in altering neurotransmission, while also producing sedation, pain relief, anti-anxiety effects, and neuroprotection. In order to achieve the "entourage effect" -the CBD is an active partner, along with other cannabinoids, terpenes, and flavinoids.